VIRALYTICS LTD SPON ADR EACH REPR 3 (NASDAQ:VRACY) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Zacks has also assigned VIRALYTICS LTD SPON ADR EACH REPR 3 an industry rank of 92 out of 265 based on the ratings given to related companies.

VIRALYTICS LTD SPON ADR EACH REPR 3 (NASDAQ:VRACY) remained flat at $2.08 on Tuesday. VIRALYTICS LTD SPON ADR EACH REPR 3 has a 12-month low of $0.74 and a 12-month high of $1.95. The firm’s market cap is $166.33 million. The firm’s 50-day moving average price is $1.49 and its 200-day moving average price is $1.44.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/viralytics-ltd-spon-adr-each-repr-3-nasdaqvracy-receives-average-rating-of-strong-buy-from-brokerages.html

About VIRALYTICS LTD SPON ADR EACH REPR 3

5 Day Chart for NASDAQ:VRACY

Get a free copy of the Zacks research report on VIRALYTICS LTD SPON ADR EACH REPR 3 (VRACY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VIRALYTICS LTD SPON ADR EACH REPR 3 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIRALYTICS LTD SPON ADR EACH REPR 3 and related companies with MarketBeat.com's FREE daily email newsletter.